Blinatumomab Expanded T-Cells
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
A.O. Ospedale Papa Giovanni XXIIICell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
117 Active assets in the Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 2 | BB |
Pegloticase M.D. Anderson Cancer Center | Phase 4 | BB |
Rasburicase M.D. Anderson Cancer Center | Phase 4 | BB |
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →